arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

DiaMedica Therapeutics Inc.

DMAC

$6.77 ▲ +0.10 (+1.50%) at close

10 Visible periods

21 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

DiaMedica Therapeutics Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $318.1M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -61.4% ↗

FCF / Share $-0.62 ↘

Trailing P/E —

Price / Book 6.5x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 6, 2026.

10-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-32.77M

↓ -34.0% —

FCF / Share Free cash flow per share

$-0.62

↓ -13.2% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
EPS Growth YoY (%)	-16.7% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	0.0% Caution ↓ Caution Declining Year-over-year change in earnings per share Optimal: > 10%	-15.4% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	20.0% Good Good Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	-34.0% Weak ↓ Weak Declining Year-over-year change in net income	-26.1% Weak ↓ Weak Declining Year-over-year change in net income	-41.7% Weak ↓ Weak Declining Year-over-year change in net income	-0.6% Weak ↑ Weak Improving Year-over-year change in net income	-10.6% Weak ↑ Weak Improving Year-over-year change in net income	-15.4% Weak ↑ Weak Improving Year-over-year change in net income	-85.7% Weak Weak Year-over-year change in net income	-34.6% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-13.2% Weak ↓ Weak Declining Year-over-year change in free cash flow	5.0% Fair ↑ Fair Improving Year-over-year change in free cash flow	-31.3% Weak Weak Year-over-year change in free cash flow	25.8% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Effective Tax Rate (%) (%)	-0.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—
FCF / Net Income (x)	0.89x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.97x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.75x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.00x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Return on Invested Capital (%)	-61.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-65.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-41.7% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-44.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-31.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-48.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-120.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-31.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-446.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-56.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-57.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-39.3% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-40.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-30.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-45.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-128.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-36.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-250.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-58.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-489%)	-60.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-500%)	-38.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-353%)	-43.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-386%)	-30.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-306%)	-47.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-415%)	-139.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1032%)	-33.7% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-325%)	—	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Interest Coverage (x)	—	—	—	—	—	—	-5796.50x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-614.64x Weak Weak Operating income divided by interest expense Optimal: > 5x	-79.28x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-15.65M	$-3.02M	$-4.54M	$-4.73M	$-4.71M	$-7.41M	$-3.88M	$-16.82M	—	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Basic EPS, GAAP (USD)	$-0.70	$-0.60	$-0.60	$-0.52	$-0.65	—	—	—	—	—
Free Cash Flow per Share (USD)	$-0.62	$-0.55	$-0.58	$-0.44	$-0.59	—	—	—	—	—
Book Value per Share (USD)	$1.04	$0.95	$1.35	$1.20	$1.66	$1.39	$0.63	$1.42	$0.13	—
Tangible Book Value per Share (USD)	$1.04	$0.95	$1.35	$1.20	$1.66	$1.39	$0.63	$1.42	$0.13	—
Basic Weighted Avg Shares (shares)	46.98M	40.40M	32.57M	26.44M	20.77M	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Working Capital (USD)	$55.50M	$39.22M	$50.89M	$31.67M	$43.91M	$25.89M	$7.52M	$16.68M	$491.00K	—
Total Equity (USD)	$56.11M	$40.72M	$51.06M	$31.83M	$44.02M	$26.01M	$7.62M	$17.02M	$799.00K	$1.11M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	—	—	—	—	$500.00K	—	—
Depreciation Expense (USD)	$43.00K	$39.00K	$30.00K	$25.00K	$24.00K	$21.00K	$21.00K	$15.00K	$4.00K	—
Net Income, GAAP (USD)	$-32.77M	$-24.44M	$-19.38M	$-13.68M	$-13.59M	$-12.29M	$-10.65M	$-5.73M	$-4.26M	—
Operating Cash Flow (USD)	$-29.06M	$-22.08M	$-18.73M	$-11.51M	$-12.25M	$-9.19M	$-9.10M	$-5.70M	$-3.90M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 35 quarters

DiaMedica Therapeutics Inc.

Analytical Summary

10-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare DMAC with peers